



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

September 14, 2022

Statement from OMB Director Shalanda Young

Budgetary Impact Analysis for Executive Order Entitled “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy”

This executive order will launch a National Biotechnology and Biomanufacturing Initiative to focus Federal investments that transform biotechnology discoveries into solutions for critical challenges facing the United States and the world. Implementing this executive order would have no impact on costs and revenues to the Federal Government. The benefits of this executive order include more robust supply chains, more domestic manufacturing, reduced carbon emissions, and better health outcomes. Implementing this executive order would have no impact on mandatory and discretionary obligations and outlays, as well as on revenues to the Federal Government, in the 5-year fiscal period beginning in fiscal year 2022. The agencies anticipated to be impacted by this executive order include the Departments of Agriculture, Defense, State, Homeland Security, Energy, Commerce, Labor, Education, and Health and Human Services, as well as the Office of the Director of National Intelligence, the National Aeronautics and Space Agency, the Environmental Protection Agency, the Census Bureau, and the National Science Foundation.